Cited 0 time in
Genomic approach to understand association between single nucleotide polymorphisms and risk of Korean serous ovarian cancer at stage IIIc
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Hyun Soo | - |
| dc.contributor.author | Kim, Yeo Jin | - |
| dc.contributor.author | Ahn, Woong Shick | - |
| dc.contributor.author | Kwon, Jee Young | - |
| dc.contributor.author | Seo, Young Rok | - |
| dc.date.accessioned | 2024-09-25T03:00:52Z | - |
| dc.date.available | 2024-09-25T03:00:52Z | - |
| dc.date.issued | 2016-03-31 | - |
| dc.identifier.issn | 1738-642X | - |
| dc.identifier.issn | 2092-8467 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/23464 | - |
| dc.description.abstract | Globally, ovarian cancer is responsible for approximately 125,000 deaths each year. Identifying the genetic contributions to ovarian cancer will lead to advances in diagnosis and therapy. Here we analyzed SNPs through genotyping in Korean serous ovarian cancer patients at stage Ilk for the purpose of applying a pathway analysis-based approach using candidate loci. The results of statistical analysis based on the Korean HapMap showed that a total of 759 SNPs had significant differences in ovarian cancer. Our biological pathway analysis included the comparison of all SNPs with SNPs of serous ovarian cancer patients in The Cancer Genome Atlas (TCGA) to identify the molecular pathway in Korean serous ovarian cancer. The results suggest that genetic alterations associated with these signaling pathways might contribute to the discovery of unique biomarkers for diagnostic predictor of Korean serous ovarian cancer at stage IIIc. | - |
| dc.format.extent | 8 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | KOREAN SOCIETY TOXICOGENOMICS & TOXICOPROTEOMICS-KSTT | - |
| dc.title | Genomic approach to understand association between single nucleotide polymorphisms and risk of Korean serous ovarian cancer at stage IIIc | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.1007/s13273-016-0004-3 | - |
| dc.identifier.wosid | 000373095200004 | - |
| dc.identifier.bibliographicCitation | MOLECULAR & CELLULAR TOXICOLOGY, v.12, no.1, pp 21 - 28 | - |
| dc.citation.title | MOLECULAR & CELLULAR TOXICOLOGY | - |
| dc.citation.volume | 12 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 21 | - |
| dc.citation.endPage | 28 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART002326477 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Toxicology | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Toxicology | - |
| dc.subject.keywordPlus | LONG-RANGE INTERACTION | - |
| dc.subject.keywordPlus | CADMIUM EXPOSURE | - |
| dc.subject.keywordPlus | BREAST | - |
| dc.subject.keywordPlus | RESPONSIVENESS | - |
| dc.subject.keywordPlus | TRANSCRIPTION | - |
| dc.subject.keywordPlus | PREVALENCE | - |
| dc.subject.keywordPlus | PROSTATE | - |
| dc.subject.keywordPlus | SURVIVAL | - |
| dc.subject.keywordPlus | MUTATION | - |
| dc.subject.keywordPlus | GENES | - |
| dc.subject.keywordAuthor | Serous ovarian cancer | - |
| dc.subject.keywordAuthor | Single nucleotide polymorphisms (SNPs) | - |
| dc.subject.keywordAuthor | Biomarker | - |
| dc.subject.keywordAuthor | Biological databases | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
